CARA Insider Trading
Insider Ownership Percentage: 3.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Cara Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Cara Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Cara Therapeutics Share Price & Price History
Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 04/15/2025 06:33 PM ET
Cara Therapeutics Insider Trading History
Cara Therapeutics Institutional Trading History
Data available starting January 2016
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Read More on Cara Therapeutics
Today's Range
Now: N/A
52 Week Range
Now: N/A
Volume
237,144 shs
Average Volume
23,945 shs
Market Capitalization
$24.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.41
Who are the company insiders with the largest holdings of Cara Therapeutics?
Who are the major institutional investors of Cara Therapeutics?
Which institutional investors are selling Cara Therapeutics stock?
During the last quarter, CARA stock was sold by these institutional investors:
- Simplex Trading LLC